AstraZeneca delays PACIFIC-9 lung cancer trial data to H1 2027
Innate Pharma (IPH, IPHA) announced AstraZeneca (AZN) delayed the PACIFIC-9 trial data to H1 2027 from H2 2026, citing the study's event-driven nature. The trial tests durvalumab with monalizumab or oleclumab in Stage III lung cancer. Monalizumab is co-developed by Innate and AZN. Innate Pharma is a clinical-stage biotech listed in Paris and on Nasdaq.
How this was made
The 30-second read
Why it matters
The postponement removes a near‑term catalyst for both AstraZeneca and Innate Pharma, likely leading to short‑term price weakness while extending the timeline for potential revenue recognition.
Market read
The delay is a fresh, material development for two listed biotech/pharma companies, affecting near‑term price dynamics.
What to watch
The delay could allow additional safety data to be gathered, possibly improving eventual trial outcomes.
Background
The PACIFIC-9 trial evaluates durvalumab combined with monalizumab or oleclumab for unresectable Stage III NSCLC. The trial enrollment is complete, and the readout was previously expected in H2 2026.
Ticker impact
AstraZeneca postponed the PACIFIC-9 Phase 3 lung‑cancer trial readout to H1 2027, delaying expected data.
likely downward pressure as the market prices in the postponed readout
Trial data is a key catalyst; pushing it back reduces near‑term upside and may trigger sell‑offs.
Innate Pharma, co‑developer of monalizumab in the AstraZeneca‑led PACIFIC-9 trial, announced the data readout delay to H1 2027.
potential short‑term decline as investors reassess timing of commercial upside
The delay directly affects Innate Pharma’s expected milestone and revenue timeline.
Market effects
May dampen sentiment in the oncology biotech sector as a key trial timeline is pushed back.
European biotech markets could see modest pressure due to the delay affecting a French‑listed company.
Limited to investors tracking AstraZeneca and related oncology partners.
Counterpoint
Some investors may view the delay as a sign of rigorous data collection, potentially supporting a longer‑term bullish stance.
Key entities
- CompanyAstraZeneca
Lead sponsor of the PACIFIC-9 trial, large multinational pharma.
- CompanyInnate Pharma
Developer of monalizumab, partner in the trial.
